Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 1

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07586826Phase 2Recruiting

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

Role: collaborator

NCT07586813Phase 2Recruiting

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors

Role: collaborator

NCT07107178Phase 1Not Yet Recruiting

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

Role: collaborator

NCT03001596Not ApplicableCompleted

Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC

Role: collaborator

All 4 trials loaded